

Proposed membership of the GDG for WHO's 2020 Virtual Meeting on the update of the Consolidated Guidelines for use of antiretrovirals for preventing and treating HIV infection

28 September – 2 October 2020

Hosted in Geneva, Switzerland

Disclaimer: In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals ("Published Information") being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO's conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO. The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publically in accordance with WHO policies.

Elaine Abrams is a Professor of Epidemiology and Pediatrics at Columbia University with over 35 years of experience in the prevention and treatment of HIV infection and associated infectious diseases in pregnant women, children, and their families. As the Senior Director for Research at ICAP, she leads ICAP's large research agenda and is responsible for the development of technical assistance and service programs for pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia. Dr. Abrams served three consecutive terms as Chair of the NIH-funded IMPAACT network HIV treatment scientific committee and currently guides the network scientific agenda as a member of the Senior Leadership Group. She chaired the WHO consolidated guidelines for the use of antiretroviral drugs since 2015, introducing universal treatment, antiretrovirals for prevention and optimized antiretroviral regimens with dolutegravir. She is also co-chair of the WHO Pediatric Antiretroviral Working Group and is actively involved in the development of policies and protocols for the study of antiretrovirals in children, adolescents, and pregnant and lactating women. Dr. Abrams' research interests have focused on maternal-child health,

mother-to-child HIV transmission, the natural history of pediatric HIV, and optimizing therapies for infants, children, adolescents and pregnant women and breastfeeding women.

Iryna Andrianova¹, Public Health Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine. Has been working since 2005, as the head of the National Reference Laboratory for HIV / AIDS Diagnostics. Functional responsibilities and qualifications: 1. Participation in the development of draft regulatory documents for the diagnosis of HIV infection within the framework of the work of multidisciplinary and intersectoral working groups approved by orders of the Ministry of Health of Ukraine. 2. Membership in working groups, committees, cooperation with international organizations (WHO, CDC, USA, UNICEF): National coordinator of the project "Introduction of the dry blood spot" method for early infant diagnosis of HIV infection", implemented with the support of the Ministry of Health of Ukraine and UNICEF in 2015-2017; Member of the WHO technical working group on the revision of guidelines for HIV testing services, 2019; Member of the multisectoral working group on preparing Ukraine for the validation procedure for the elimination of HIV and syphilis from mother to child; external expert on the preparation of the Republic of Uzbekistan for the validation of the elimination of HIV from mother to child (assessment of the organization and implementation of measures for laboratory diagnosis of HIV infection, 2019).

Moherndran Archary is a Paediatric Infectious Disease Specialist in the Department of Paediatrics and Child Health at King Edward VIII Hospital affiliated to the Nelson R Mandela School of Medicine, University of KwaZulu-Natal. He is actively involved with the management of children and adolescents with HIV and other infectious diseases and serves on several national and international technical task teams and guideline committees. He is the current co-chair of the WHO Paediatric ARV Working Group (PAWG). His research interests include antiretroviral drug therapeutics, viral resistance, optimal timing of initiation of antiretroviral therapy and optimal adolescent HIV treatment in the developing world. He is the vice-chair of the Treatment Scientific committee in the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. He serves as the principal investigator on several studies focusing on the investigation of novel ARV and TB therapies in children through the IMPAACT, PENTA and other networks.

Helen Ayles is a Professor of Infectious Diseases and International Health in the Clinical Research Department at the London School of Hygiene and Tropical Medicine, and has lived in Zambia for more than 20 years working at Zambart in Lusaka. After training in clinical infectious and tropical diseases in the UK she trained in epidemiology at the London School of Hygiene and Tropical Medicine. Helen's research interest is in the combined epidemics of TB and HIV and in the evaluation of large public health interventions. She is the Zambia principal investigator for the PopART trial (HPTN071), a large community-randomized trial of treatment as prevention for HIV and the overall PI of the TREATS consortium, and EDCTP funded study evaluating the effect of the PopART intervention on tuberculosis. Helen also has studies investigating how best to scale up sexual and reproductive health interventions for

¹ Nomination from the Ukraine within the two-week period before the Guidelines meeting.

adolescent girls and young women. Helen is a member of the Technical Review Panel for the Global Fund.

Solange Baptiste is the Executive Director of the International Treatment Preparedness Coalition (ITPC). She leads community activists and allies across the globe to deliver ITPC's mission to enable people in need to access optimal and affordable HIV treatment through health and treatment education, demand creation, community-based monitoring & advocacy and interventions to make medicines more affordable. Solange has over 15 years of global program management and advocacy experience and specializes in monitoring and evaluation. She has a depth of knowledge in social epidemiology, health financing and community systems strengthening in the developing world through her work on USAID/PEPFAR health and development, bilateral and multi-county projects across Africa and Asia. She earned a Bachelor of Science in Biology from Tuskegee University and her Master of Science in Population and International Health from the Harvard School of Public Health. Solange is committed to ensuring that the voice of affected communities contributes to and influences the decisions and policies that affect their lives.

Pedro Cahn is Professor of Infectious Diseases at the Buenos Aires University Medical School. Dr Cahn has been working in infectious diseases for the last 40 years, and has been involved in the HIV/AIDS area since 1982. He has served as Chief of Infectious Diseases at the Juan Fernandez Hospital in Buenos Aires, Argentina, where he is now a senior consultant. He is Scientific Director at Fundación Huésped, the largest NGO in Argentina, serving patients with, or at risk of, HIV/AIDS. Dr Cahn's team has contributed to identifying new treatment strategies and promoting research on dual therapy. He is also Co-Chair of CCASAnet (the Caribbean, Central and South American network), a cohort part of leDEA, and investigator with the IMPAACT network. He is a past president of the International AIDS Society, and has served as an external advisor to UNAIDS, the World Health Organization (WHO), the Pan-American Health Organization (PAHO), Unitaid and MSF. He is a member of the WHO Antiretroviral Guidelines Panel, Chair of the Treatment Advisory Group at PAHO, and a former member of the Guidelines Panel of the International Antiviral Society – United States of America (USA). He is part of the Technical Advisory Committee on HIV at the National AIDS Programme in Argentina. He has served as external advisor for the ARV guidelines panel in Mexico, South Africa and Uruguay. Dr Cahn has published more than 200 peer-reviewed papers and book chapters.

Alexandra Calmy is a medical doctor, trained in internal medicine and infectious diseases (FMH). She holds a PhD in clinical research in HIV/AIDS obtained in Sydney, Australia. She is currently a full Professor, and the Head of the HIV/AIDS Unit at Geneva University Hospitals. Pr Calmy's research interest is in the public health and humanitarian response to HIV/AIDS, specifically the provision of ART and management of side effects in resource-limited settings. In 1996, she worked as a medical doctor with MSF in Cambodia; she has subsequently supported MSF's HIV/AIDS work for over 10 years. Since 2001, she has been a member of the WHO working groups on the writing and implementation of guidelines related to the treatment of HIV in developing countries. She is also co-Lead of the CSS13 Committee at the

Agence Nationale de Recherche sur le SIDA (ANRS, France), a member of the Scientific Board of the Swiss HIV Study Cohort, of the Federal Commission of Sexual Health, and of the National COVID-19 Science Task Force in Switzerland. She is also a reviewer for numerous well-recognized medical journals, and has published over 200 articles in peer-reviewed medical journal.

Mohamed Chakroun is a Medical Doctor specialist in Infectious Diseases. He works full-time in the University Hospital of Monastir, Tunisia, and He's Professor in the Faculty of Medicine. As a physician, He provides care and support for people living with HIV, and has extensive experience in HIV care, ART and prevention. He has been engaged with national AIDS programmes, community groups and health organizations in HIV care, prevention and policy development for several years. He is also a national and regional expert on HIV/AIDS. He was Scientific Coordinator for the Tunisian Guidelines for Antiretroviral Therapy in 2010 and 2013. He provided training on HIV testing counselling, ART, management of opportunistic infections, and prevention of mother-to-child transmission (PMTCT) in Djibouti, Egypt, Libya, Sudan and Tunisia. He provided technical support to the HIV/AIDS, Hepatitis and Sexually Transmitted Infections (STI) Unit in the WHO Regional Office (Cairo, Egypt). He has written many national and regional manuals on HIV/AIDS, as well as several papers on HIV/AIDS in peer-reviewed journals. He attended several WHO regional workshops and inter-country meetings of national AIDS programme managers as temporary advisor. He was a member of the external review group for WHO's consolidated guidelines for key populations (2014), HIV testing services (2015), and HIV self-testing (2016). He was also a member of the WHO Guideline Development Group for HIV post-exposure prophylaxis (2014) and the use of antiretroviral drugs (2016 and 2018). Currently, he is a member of the Global Network of Researchers on HIV/AIDS in the Middle East and the HIV Drug Resistance Network.

Paul Drain, MD, MPH, is Associate Professor in the Departments of Global Health, Medicine (Infectious Diseases), and Epidemiology at the University of Washington and a practicing Infectious Disease physician at Harborview Medical Center and the University of Washington Medical Center in Seattle. His research group focuses on development, evaluation and implementation of diagnostic testing and clinic-based screening, including novel point-of-care technologies, to improve clinical care and patient-centered outcomes for tuberculosis and HIV in resource-limited settings. He is Associate Director of the Tuberculosis Research and Training Center at the University of Washington. His research has been supported by several institutes of the National Institutes of Health, the Infectious Disease Society of America, Bill and Melinda Gates Foundation, Harvard Global Health Institute, both the UW's and Harvard's Center for AIDS Research, and the AIDS Healthcare Foundation. He has authored several global health books and received awards from Infectious Disease Society of America, and a Faculty Teaching Award from Harvard Medical School.

Tendani Gaolathe is a medical doctor who has served as Principal Investigator to 2 cooperative agreements through the Botswana Harvard AIDS Institute Partnership President's Emergency Plan for AIDS Relief (PEPFAR) training and capacity-building programme. She has over 15 years of experience in capacity-building in training, mentoring

and supervision of public health initiatives in both the government and private sector. She has experience in the development of training guidelines, manuals and curriculums with content on HIV/AIDS. In addition to her capacity-building skills, she has significant experience developing national guidelines on the care and management of HIV/AIDS interventions. She has been Chair of the National HIV/AIDS Treatment Guidelines Committee since 2007, and has led a team that influenced the national response in changing guidelines for HIV care and management, drug forecasting and budgeting, which resulted in the development and dissemination of national HIV/AIDS treatment guidelines. She has been involved in clinical research, currently serving as Project Director and Co-Investigator for the just ending Botswana Combination Prevention Project, in conjunction with the Harvard School of Public Health, Ministry of Health and Centers for Disease Control and Prevention (CDC), which focuses on offering and implementing an intervention package that will affect the incidence of HIV at the community level. She also serves as country representative for the Botswana–Rutgers Global Health Initiative and lectures at the Faculty of Medicine, University of Botswana.

Eric Goemaere is a medical doctor and economist by training. His career with MSF started in 1982, working in Chad and afterwards in several field missions, interrupted by postings to MSF Headquarters, to be MSF Brussels Medical Director (1988–1991) and MSF Brussels General Director (1994–1999). In 1999 Dr Goemaere migrated to South Africa to pioneer MSF's first public health ARV programme in Khayelitsha. Since then, Eric has occupied numerous positions running MSF's HIV/TB projects in South Africa, finally joining SAMU in 2009, where he is currently the HIV/TB Unit Coordinator, providing support and training for MSF Brussels HIV/TB projects in the region. Eric has received an Honoris Causa Doctorate from the University of Cape Town for his work in HIV, and has been appointed Honorary Senior Lecturer in the School of Public Health and Family Medicine. He is currently associated with several operational research initiatives, as well as numerous publications. He is a member of the South African AIDS Council and the WHO guidelines advisory board.

Beatriz Grinsztejn is an infectious diseases physician and researcher at the Evandro Chagas National Institute of Infectious Diseases-Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. She holds a PhD in Infectious Diseases obtained at the Federal University of Rio de Janeiro Brazil. Dr Grinsztejn is the Director of the STD/AIDS Clinical Research Laboratory and principal investigator of the FIOCRUZ HIV Prevention and Therapeutic Clinical Trials Unit at FIOCRUZ. The unit is affiliated to the HIV Prevention Trials Network, the AIDS Clinical Trials Group, the HIV Vaccine Trials Network, the COVID 19 Prevention Trials Network and the ANRS, and implements HIV and COVID 19 prevention and therapeutic clinical trials and cohort studies. Dr Grinsztejn is the Brazilian principal investigator for the Caribbean, Central and South America network for HIV epidemiology of the International Epidemiologic Databases to Evaluate AIDS. She is a member of the Brazilian Ministry of Health ART and PrEP Advisory Committees, PAHO Technical Advisory Committee and PrEP Task Force and a member of the IAS Governing Council. Dr Grinsztejn is a faculty member of the Masters and PhD Degree Program on Clinical Research in Infectious Diseases at the Oswaldo Cruz Foundation. She conducted some pivotal studies that have changed the landscape of HIV and TB prevention and treatment and has published more than 330 peer-reviewed publications.

Diane Havlir is Professor of Medicine and Associate Chair of Clinical Research at the University of California, San Francisco, and Chief of HIV, Infectious Diseases and Global Medicine at San Francisco General Hospital. She was a physician in training when the AIDS epidemic emerged in the 1980s, and has cared for HIV-infected patients ever since. She has conducted clinical research in HIV and coinfections for over 25 years, with more than 300 publications. Her research focus areas include the study of antiretrovirals, HIV and coinfections (TB and malaria), and community-based interventions. She is currently leading several trials focused on strategies to optimize implementation of ART and TB prevention. Her group is conducting a large community randomized study in East Africa measuring the health, economic and education effects of testing and treatment using a patient-centered, streamlined care model. She led WHO's TB/HIV Working Group, served as chair of the WHO Global HIV Drug Resistance Surveillance Network, and has participated on the WHO Guidelines Review Committee since its inception.

Andreas Jahn is a clinical epidemiologist with 20 years of working experience in Africa, primarily in HIV. He has worked in the academic and program sector. Dr Jahn has published over 100 papers in peer-reviewed journals, including the first evidence globally for a population-level impact of ART roll-out on adult mortality (The Lancet, 2008). He has worked with the International Training and Education Center for Health (I-TECH, University of Washington, Seattle) as technical assistant for the National ART/PMTCT Program in Malawi since 2008. He has made a profound contribution to the national roll-out of ART and PMTCT and shaped the integrated M&E system for the HIV program in Malawi. He holds a position as Clinical Associate Professor in the Department for Global Health at UW. He continues to contribute to national and international HIV programs and policy with innovative monitoring systems and initiatives such as Option B+ for PMTCT, which has been adopted as a global recommendation by WHO in 2013.

Ilesh Jani is the Director General of the Instituto Nacional de Saúde (INS) at Mozambique's Ministry of Health. Dr. Jani has been a researcher at the INS since 1998, where he also served as the Head of the Department of Immunology. Dr. Jani qualified as a medical doctor at the Eduardo Mondlane University in Mozambique and received a Ph.D. in immunology from the University of London in the United Kingdom. During his career Dr. Jani has lead efforts in the areas of research, public health, education and diagnostics with the objective of strengthening the health system in Mozambique. His research interests include HIV vaccines and diagnostics, including the deployment of these health technologies in resource-limited health systems. Dr. Jani is currently a member of WHO's Strategic Advisory Group of Experts on Immunization (SAGE).

John Kinuthia is an Obstetrician Gynecologist and Head of Research and Programs at Kenyatta National Hospital, an honorary lecturer at the University of Nairobi Institute of Tropical and Infectious Diseases and the Department of Obstetrics and Gynaecology and Affiliate Associate Professor, Department of Global Health. Dr Kinuthia's research has focused on evaluation of uptake and utilization of PMTCT interventions; understanding incidence and cofactors of HIV

incidence during pregnancy and after delivery; and HIV prevention interventions including the use of pre-exposure prophylaxis (PrEP) during pregnancy and breastfeeding. Dr Kinuthia received his undergraduate and postgraduate training at the University of Nairobi. He received a Master's in Public Health at the University of Washington. He is the site Principal Investigator on several studies on PrEP use among pregnant and breastfeeding women, optimizing PrEP delivery in Maternal Child Health and Family Planning Clinics and interventions to improve maternal and infant health. He is a member of the PMTCT and PrEP/HTS Technical Working Groups coordinated by NASCOP Kenya.

Nagalingeswaran Kumarasamy is the Director and Chief of VHS-Infectious Diseases Medical Centre, where he oversees the clinic that provides medical care for more than 20,000 people living with HIV in Chennai, Southern India. Dr Kumarasamy is also the Director and Site Leader of the Chennai Antiviral Research and Treatment Clinical Research Site of the US National Institutes of Health (NIH), which conducts multisite therapeutics (ACTG) and prevention (HPTN) clinical trials. He is the Chennai site's Principal Investigator for ACTG, HPTN and START clinical trials. He is involved as Clinical Investigator for several ongoing clinical research projects with the University of California, San Diego, Harvard University, Boston and Brown University, USA. Dr Kumarasamy is a clinician and researcher in infectious diseases with more than 20 years of experience in the field of medicine. He has published more than 400 manuscripts in peer-reviewed medical journals. His publications on the impact of antiretroviral therapy have led to several antiretroviral scale-up programmes in developing countries. Dr Kumarasamy has been an expert panel member of the WHO ARV Treatment guidelines committee since 2003, and is a clinical advisor to the Clinton Health Access Initiative (CHAI). He has an interest in the long-term impact of ART in resource-limited settings. Currently he serves on the National Task Force for COVID Clinical Research and Drug Development.

Inga Latysheva² is an Infectious Disease Specialist, working in Republican Clinical Hospital of infectious diseases Ministry of Healthcare Russian Federation as Deputy Chief Physician. She has been working in infectious diseases more than the last 25 years, and has been involved in the HIV/AIDS area since 2008. Dr. Latysheva conducts monitoring and supervision of the healthcare facilities for pregnant women and children with HIV infection in the Russian Federation regions, supervises over the modern methods of HIV infection diagnosis, prevention and treatment implementation in the Russian Federation. She is a coordinator of the HIV infection diagnosis and treatment activities for AIDS Prevention and Control Centres in 85 regions of the Russian Federation. She is a member of the national Russian Antiretroviral Guidelines Panel, member of the WHO High Level Working Group on HIV Treatment Group in Russia. She has been a member of the WHO working groups on the writing and implementation of guidelines related to the testing of HIV, EACS guidelines of management HIV. She is actively involved in the management of children with HIV at both national and international levels, especially working with adolescents. She teaches HIV, especially PMTCT questions, working with and contributing to improve health outcomes in children, adolescents, women as priority population groups. As a physician, he provided care and

² Nomination from the Russian Federation within the two-week period before the Guidelines meeting.

support for people living with HIV, and has extensive experience in HIV care, ART and prevention. She is currently evaluating strategies to optimize adherence and efficacy of PMTCT/ART and strategies to deliver PrEP during pregnancy. He is a Head of the PMTCT guidelines developing group. She is involved in policy formulation and guideline development of PMTCT/ART in children in Russia.

Imelda Chipso Mahaka is the Country Director for Pangaea Zimbabwe AIDS Trust in Harare, Zimbabwe, providing programmatic and operational oversight to the organisation. She has been involved in policy advocacy, community engagement and implementation around HIV prevention and treatment optimization including scale-up of treatment and access to diagnostics and monitoring. She has over 15 years of experience in managing and coordinating programs, training, including experience in the development of training manuals and curriculums with content on HIV/AIDS for adolescents. More recently, her work has branched into introduction and scale up of prevention products advocating for more options for women and girls in Zimbabwe. Formerly with the UZ-CHS Research Programme and Zimbabwe AIDS Prevention Project, Imelda has extensive experience in HIV/AIDS and behavioural research on sexual and reproductive health especially working with adolescents. Imelda is a certified social worker, project manager and researcher, with a passion for working with and contributing to improved health outcomes for adolescents, women and other priority population groups. An avid activist, she is a member of AfroCAB and the CHAI-Unitaid Optimal ARV Project Community Advisory Board, working towards empowered communities. She also sits on a number of study trials committees representing communities. Imelda is a member of the Viral Load, DSD and PrEP Technical Working Groups coordinated by MOHCC Zimbabwe and served as secretariat to the Laboratory partnership Forum for a number of years.

Angela Mushavi is the National PMTCT and Paediatric HIV Care and Treatment Coordinator in Zimbabwe's Ministry of Health and Child Care. She provides technical leadership and guidance for the expansion of PMTCT and paediatric HIV and AIDS care and treatment programmes in Zimbabwe. She is involved in policy formulation and guideline development at both national and international levels. Dr Mushavi has provided technical expertise to the WHO HIV guidelines development process since 2010, when she was an external reviewer to the PMTCT guidelines. Since then, she has been a member of the WHO GDG in subsequent WHO guideline revisions, and a member of the technical experts reviewing infant HIV testing and prophylaxis recommendations. Dr Mushavi leads the work on elimination of mother-to-child transmission of HIV in Zimbabwe, and is a member of the WHO Global Validation Advisory Committee that supports global efforts by countries to be recognized as having attained criteria for validation of dual elimination of mother-to-child transmission of HIV and syphilis. Prior to joining the Ministry of Health and Child Care in 2010, Dr Mushavi worked with CDC Namibia as a PMTCT Technical Advisor to the Namibian Ministry of Health and Social Services. She also managed a large paediatric ART clinic in Windhoek, providing care and treatment to HIV-exposed and HIV-positive children and adolescents. A strong advocate for the care of children affected by HIV and AIDS, Dr Mushavi sits on the Steering Committee of the African Network for the Care of Children Affected by HIV.

Landon Myer is Head of the School of Public Health and Family Medicine at the University of Cape Town, South Africa, where he is also a Professor in the Division of Epidemiology and Biostatistics. He has a background in anthropology, clinical medicine and epidemiology. His research centres around women's, maternal and child health in the context of HIV/AIDS. This includes clinical and health system studies, with a particular interest in the health of HIV-infected women receiving ART during pregnancy, and the health and development of their children. He has been involved previously in WHO guidelines related to ART, as well as hormonal contraception.

Kogieleum Naidoo, MBCHB, PhD, is the clinical head of the HIV and TB Treatment Research Program at the Centre of the AIDS Programme of Research in South Africa (CAPRISA), and Honorary Associate Professor in the College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. Her contribution to HIV and TB treatment spans over two decades. Dr Naidoo was lead PI on several CAPRISA studies that have shaped both local and international guidelines on TB-HIV treatment integration. She has been a lead investigator in several Phase II and III TB-HIV and drug resistant-TB treatment trials. These include several international, multicentred, multi-country collaborative clinical trials. She has supervised post-doctoral, doctoral, and masters' candidates, authored peer reviewed publications, and co-authored chapters in several global health books. She is the editor of the Casebook, Radiological Features of TB in HIV Co-infected Patients. In 2013, she received the Union Scientific Prize for her scientific contributions in TB awarded by the International Union against Tuberculosis and Lung Disease.

Nicaise Ndembi is Director of Laboratory Research at the Institute of Human Virology Nigeria (IHV- Nigeria); Adjunct Associate Professor of the Division of Epidemiology and Prevention at the IHV, University of Maryland School of Medicine, USA; and Research Professor of the Global Affairs Section of Kanazawa University, Japan. Before that, Dr Ndembi was head of the Virology Laboratory at the Uganda Virus Research Institute (MRC/UVRI and LSHTM Uganda Research Unit), where he supported several multi-country randomized controlled trials on HIV treatment strategy, including the CDC cluster- randomized trial to compare the effectiveness of home-based versus facility-based delivery of ART (Lancet 2009), and the United Kingdom Medical Research Council DART trial (Lancet 2010). Dr Ndembi has served on several scientific advisory panels, and continues to serve as an advisor on HIV drug resistance and control policy to Nigeria's Federal Ministry of Health. He is a member of the PharmAccess Technical Advisory Board for the Pan-African Studies to Evaluate Resistance in Africa (Lancet Infectious Diseases 2012). Dr Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Health. He has coauthored more than 110 publications in peer- reviewed journals and received numerous awards. Dr Ndembi's main research interest is HIV vaccines, especially understanding protective immune responses, genomics epidemiology, microbiome, HFV, HIV diversity and resistance to ARV.

Roger Paredes, MD, PhD, is a Section Chief, Infectious Diseases Department Hospital Germans Trias i Pujol and Head of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, both in Badalona, Catalonia, Spain. Roger Paredes obtained an MD, PhD degree in

Medicine and Surgery from the Autonomous University of Barcelona (UAB). He specialised in HIV resistance at the Brigham & Women's Hospital in Boston and Harvard Medical School. His team has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries. Dr. Paredes is member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee and the International Antiviral Society-USA, which annually produces the IAS-USA list of HIV-1 drug resistance mutations, used worldwide. He is co-author of the Rega algorithm for HIV resistance interpretation and virologist and Vice-chair for the EuroSIDA cohort. His group is presently leading pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. Dr. Paredes has coordinated the clinical management of hospitalized COVID-19 subjects and has been Spanish coordinator for several NIH-funded seminal COVID 19 therapeutic RCTs such as ACTT-1, ACTT-2, ACTIV-3.

Nittaya Phanuphak is currently the Executive Director at the Institute of HIV Research and Innovation in Bangkok, Thailand. She has deep interest in HIV prevention and key populations (KP), especially around the use of Key Population-Led Health Service (KPLHS) approaches to enhance access to HIV testing, prevention and treatment among men who have sex with men (MSM) and transgender women (TGW). She currently works actively with community and government partners to establish a national technical assistance platform to support the accreditation and legalization of KP lay providers to ensure KPLHS sustainability through domestic financing mechanism. In 2015, she supported the establishment of the Tangerine Community Health Clinic using integrated hormone therapy and sexual health service approach to effectively bring almost 4,000 transgender clients into services over a 4-year period. The model is currently being expanded to community-based organizations, as well as public and private clinics, in the Asia Pacific region. Dr Phanuphak also oversees the KP-led Princess PrEP program, HPTN 083 and HIV self-testing and PrEP project for MSM and TGW aged 15-19 years in Thailand. In 2017, she started same-day ART initiation program in Bangkok which has led to its recommendation in 2020 Thailand National HIV Treatment and Prevention Guidelines. Dr Phanuphak has served as the Asia Pacific representative in the IAS Governing Council since 2018.

Raja Iskandar Shah Raja Azwa is an Associate Professor in Infectious diseases, Faculty of Medicine, University of Malaya with a sub-speciality interest in Sexual Health and HIV Medicine. He is also the Clinical lead for HIV services at the University of Malaya and was previously the Head of Infectious Diseases Unit from 2014-2016. He also is a clinical associate at the Centre for Excellence of Research in AIDS (CERIA), University Malaya and was the recipient of CIRA international fellowship from Yale University in 2017. He is currently the Honorary Secretary at the Malaysian AIDS Council and is the Chair of the National PrEP Working Group. His research interests include clinical research of newer antiretroviral treatment (ART) strategies, HIV resistance, HIV PrEP implementation among key populations and sexual health service development in resource limited settings. He is an experienced clinician and researcher on HIV treatment and management, and is the site Principal Investigator for key clinical studies such as the START, D2EFT and important cohort studies such as the TREAT Asia HIV Observational database (TAHOD), and more recently on issues surrounding HIV viral load quantification.

Nandi Siegfried is a South African public health physician working as an independent clinical epidemiologist based in Cape Town. Following several years in clinical practice, she transitioned to a research career focused on clinical epidemiology and trials methods. She worked for a decade at senior management level at the South African Medical Research Council, where she was co-director of the South African Cochrane Centre and Deputy Co-coordinating Editor of the Cochrane HIV/AIDS Review Group. In 2011 she commenced working independently. In this capacity she provides assistance and guidance, as well as technical support to international, national, institutional and non-government agencies in the healthcare sector. She has worked closely with the World Health Organization as Chair, Technical Advisor and/or Methodologist to over 20 WHO Clinical Guidelines Development Groups and served as the South African representative on the Organization for Cooperation and Economic Development Working Group on Multinational, Non-commercial Clinical Trials. She has a thorough knowledge of the methods required for high quality clinical trial conduct and is highly experienced in systematic review methodology, knowledge translation and guidelines development. Her public health training affords her a broad perspective across the healthcare arena and as a South African, she has experience and knowledge of the healthcare challenges facing low- and middle-income countries. She has published widely and enjoys teaching and lecturing.

Tapwia Tarumbiswa is the HIV & AIDS Manager in the Ministry of Health Lesotho. He is the head of the HIV program, chairperson of the national 2nd Line ART committee and national HIV technical working group in Lesotho. He has over 12 years HIV programming experience in both public and private sectors, currently responsible for the development of HIV policy, strategy and guidelines in the Ministry of Health Lesotho. Dr Tarumbiswa is a researcher, the most recent work he has done has been a co-author of the Lesotho Population Based HIV Impact Assessment 2020. Dr Tarumbiswa was the Medical Director of Baylor Qacha's Nek Satellite Clinic and founded the Qacha's Nek peanut butter program for malnourished children living with HIV in 2010. He was the Founder and Medical Director of Baylor Queen Mammohato Adolescent Clinic in 2012, has served as Board Member for World Vision Lesotho. Prior to being assigned to the position of HIV & AIDS manager in the ministry of health Dr Tarumbiswa was the Medical Director for the AIDS healthcare Foundation Lesotho (AHF) 2015, where over 2 years grew the HIV patient census receiving HIV care from 1246 patients on ART- June 2015 to 11,377 patients May 2017.

Anna Turkova is a paediatrician at the Great Ormond Street Hospital, London and a research clinician at the Medical Research Council Clinical Trials Unit at University College London (UCL). She graduated in the Russian Federation and has been working in the United Kingdom since 2002. Her research activities are focused on HIV, TB, hepatitis C virus and coinfections. Dr Turkova is a trial clinician in several large international paediatric HIV and TB randomized controlled trials run by the Medical Research Council Clinical Trials Unit at UCL. She coordinates epidemiological and observational collaborative studies in Eastern Europe. At Great Ormond Street Hospital, as part of the Infectious Diseases team, she manages children and families affected by HIV, viral hepatitis and TB. Dr Turkova is a member of the WHO-led Paediatric Drug Optimization and Paediatric Antiretroviral working groups. She is also a

steering committee member of the Paediatric European Network for Treatment of AIDS and Other Infectious Diseases (PENTA-ID). She co-chaired the clinical guidelines developing group for the PENTA HIV treatment guidelines in 2015, and was part of the writing group of the 2016-2019 editions. Dr Turkova facilitates online and residential PENTA HIV and TB training courses in Western and Eastern Europe and Africa, and teaches on Master of Science in Clinical Trials at the Medical Research Council Clinical Trials Unit at UCL.

Alexandra Volgina is a positive activist and an expert in organizing care and treatment for active drug users living with HIV in Russia. In 2003, she co-founded FrontAIDS, the first treatment advocacy group in Russia. She later co-founded and became director of Svecha, one of the first community-based organizations for people living with HIV. Today Alexandra runs “E.V.A”—the first network for women with HIV in Russia and is an active member of the “Patients in Control” treatment access movement. Alexandra, or Sasha, is based in Netherlands with her family.

Jacqueline Wambui Mwangi leads the CHAI-Unitaid Optimal ARV Project Community Advisory Board, at the Afrocab Treatment Access Partnership. Jacqueline’s education background is in HIV counselling and training. She is an HIV- positive activist who has a special interest in the rights of HIV-positive people and advocating on their behalf. She has more than 10 years’ experience actively working in programs focused on HIV and sexual and reproductive health and rights in Kenya. Her work experience has seen her take the lead in various advocacy campaigns that affect people living with HIV in Kenya, regionally and globally. She also co leads the FASTER Pediatric and Adolescent CAB. Jacqueline is also a consultant with AVAC and is a member of the Global Community Advisory Group for the ECHO Study.